Objectives: The aim of the present study is to investigate the efficacy of the Velumount® device. Methods: In a prospective cohort study 40 patients were examined with and without Velumount. The apnea-hypopnea index and average esophageal pressure were measured using nocturnal manometry of the upper airways, combined with respiratory polygraphy. The snoring index (1–10) and daytime sleepiness using the Epworth Sleepiness Scale were assessed by means of a questionnaire. Results: Using Velumount the snoring index was reduced from on average 8.4 (SD ± 1.3) to 3.7 (SD ± 2.5), the Epworth Sleepiness Scale score from on average 7.9 (SD ± 4.4) to 3.8 (SD ± 3.4) and esophageal pressure from on average 14.8 cm H2O (SD ± 6.7) to 11.2 cm H2O (SD ± 6.4). In patients (n = 25) with obstructive sleep apnea, the average apnea-hypopnea index was 24.3 (SD ± 10.1) without and 13.6 (SD ± 12.2) with Velumount. All changes were highly significant. Conclusions: TheVelumount device is effective for the treatment of snoring and obstructive sleep apnea. The effect is similar to that reported from uvulopalatopharyngoplasty.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.